{"sent_idx": "113", "frame_idx": "13", "ev": "Additionally, stratified analysis by gender did not show differences between placebo and RMD groups for CTT and SCTT (data not shown).Table 2Change in total, right, left and rectosigmoidal colonic transit time for each group after 3-week intervention", "icos": [["1", "RMD", "placebo", "SCTT"]], "sample": "x"}
{"sent_idx": "113", "frame_idx": "14", "ev": "Additionally, stratified analysis by gender did not show differences between placebo and RMD groups for CTT and SCTT (data not shown).Table 2Change in total, right, left and rectosigmoidal colonic transit time for each group after 3-week intervention", "icos": [["1", "RMD", "placebo", "rectosigmoidal colonic transit time"]], "sample": "x"}
{"sent_idx": "11", "frame_idx": "2", "ev": "Significant time-by-treatment interaction was observed in the RMD group for stool volume (p = 0.014), increasing 56 % compared to baseline (p < 0.01), while remained unchanged in the placebo group.", "icos": [["0.9959194", "placebo", "Dietary supplementation of RMD", "stool volume"], ["0.9954659", "placebo", "abdominal X - ray", "stool volume"], ["0.9947278", "placebo", "DF intake", "stool volume"], ["0.99444526", "placebo", "fructo - oligosaccharides ( FOS )", "stool volume"], ["0.9942334", "placebo", "RMD", "stool volume"]], "sample": "c"}
{"sent_idx": "24", "frame_idx": "7", "ev": "Significant time-by-treatment interaction was observed in the RMD group for stool volume (p = 0.014), increasing 56 % compared to baseline (p < 0.01), while remained unchanged in the placebo group.", "icos": [["0.9959194", "placebo", "Dietary supplementation of RMD", "stool volume"], ["0.9954659", "placebo", "abdominal X - ray", "stool volume"], ["0.9947278", "placebo", "DF intake", "stool volume"], ["0.99444526", "placebo", "fructo - oligosaccharides ( FOS )", "stool volume"], ["0.9942334", "placebo", "RMD", "stool volume"]], "sample": "c"}
{"sent_idx": "110", "frame_idx": "10", "ev": "The total CTT, left SCTT and rectosigmoidal SCTT were significantly decreased in the RMD group after intervention compared to baseline (p < 0.004, p < 0.008 and p < 0.006, respectively), while no decrease was found in the placebo group.", "icos": [["0.99534976", "placebo", "abdominal X - ray", "total CTT , left SCTT and rectosigmoidal SCTT"], ["0.99389994", "placebo", "Dietary supplementation of RMD", "total CTT , left SCTT and rectosigmoidal SCTT"], ["0.9938379", "placebo", "DF intake", "total CTT , left SCTT and rectosigmoidal SCTT"], ["0.99239516", "placebo", "soluble corn fibre", "total CTT , left SCTT and rectosigmoidal SCTT"], ["0.9890027", "placebo", "hydrochloric acid", "total CTT , left SCTT and rectosigmoidal SCTT"]], "sample": "c"}
{"sent_idx": "112", "frame_idx": "12", "ev": "Placebo intervention did not yield any decrease for the total CTT and SCTT.", "icos": [["0.9907194", "Placebo", "DF intake", "total CTT and SCTT ."], ["0.98825663", "Placebo", "hydrochloric acid", "total CTT and SCTT ."], ["0.98390794", "Placebo", "RMD", "total CTT and SCTT ."], ["0.9812072", "Placebo", "fructo - oligosaccharides ( FOS )", "total CTT and SCTT ."], ["0.98094773", "Placebo", "placebo - controlled", "total CTT and SCTT ."]], "sample": "c"}
{"sent_idx": "115", "frame_idx": "15", "ev": "After the intervention period, there were significant increases in defecation frequency in both groups compared to baseline (RMD 65.8 %, placebo 56.1 %; p < 0.01 each).", "icos": [["0.9919544", "placebo", "Dietary supplementation of RMD", "defecation frequency"], ["0.9906825", "placebo", "fructo - oligosaccharides ( FOS )", "defecation frequency"], ["0.9898583", "placebo", "hydrochloric acid", "defecation frequency"], ["0.98945767", "placebo", "RMD", "defecation frequency"], ["0.9889002", "placebo", "abdominal X - ray", "defecation frequency"]], "sample": "c"}
{"sent_idx": "120", "frame_idx": "20", "ev": "No change was observed in the placebo group for the stool consistency.", "icos": [["0.98559463", "placebo", "hydrochloric acid", "stool consistency ."], ["0.9810497", "placebo", "placebo ( maltodextrin )", "stool consistency ."], ["0.9775733", "placebo", "DF intake", "stool consistency ."], ["0.9769057", "placebo", "RMD", "stool consistency ."], ["0.9760442", "placebo", "Dietary supplementation of RMD", "stool consistency ."]], "sample": "c"}
{"sent_idx": "121", "frame_idx": "21", "ev": "Regarding the total number of Rome III positive criteria, there were significant reductions in both RMD and placebo groups (p < 0.01 each).Table 3Change in stool volume and stool consistency for each group during 3-week intervention  Interestingly, analysis of the individual Rome III criteria showed that only after intervention with RMD a significant lower number of subjects (compared to baseline) answered positively to 3 out of 6 criteria: \"straining\" (from 63.6 to 33.3 %; p < 0.025), \"sensation of incomplete evacuation\" (from 51.5 to 27.3 %; p < 0.003) in at least 25 % of defecations, as well as \"fewer than three defecations per week\" (from 24.2 to 0.0 %; p < 0.013).", "icos": [["0.99161595", "placebo", "Dietary supplementation of RMD", "\" straining \""], ["0.98831534", "placebo", "DF intake", "\" straining \""], ["0.9874385", "placebo", "soluble corn fibre", "\" straining \""], ["0.98722225", "placebo", "radiopaque markers", "\" straining \""], ["0.9866583", "placebo", "abdominal X - ray", "\" straining \""]], "sample": "c"}
{"sent_idx": "121", "frame_idx": "22", "ev": "Regarding the total number of Rome III positive criteria, there were significant reductions in both RMD and placebo groups (p < 0.01 each).Table 3Change in stool volume and stool consistency for each group during 3-week intervention  Interestingly, analysis of the individual Rome III criteria showed that only after intervention with RMD a significant lower number of subjects (compared to baseline) answered positively to 3 out of 6 criteria: \"straining\" (from 63.6 to 33.3 %; p < 0.025), \"sensation of incomplete evacuation\" (from 51.5 to 27.3 %; p < 0.003) in at least 25 % of defecations, as well as \"fewer than three defecations per week\" (from 24.2 to 0.0 %; p < 0.013).", "icos": [["0.9913374", "placebo", "Dietary supplementation of RMD", "stool volume and stool consistency"], ["0.9885675", "placebo", "abdominal X - ray", "stool volume and stool consistency"], ["0.98839545", "placebo", "hydrochloric acid", "stool volume and stool consistency"], ["0.9871737", "placebo", "radiopaque markers", "stool volume and stool consistency"], ["0.9865328", "placebo", "DF intake", "stool volume and stool consistency"]], "sample": "c"}
{"sent_idx": "121", "frame_idx": "23", "ev": "Regarding the total number of Rome III positive criteria, there were significant reductions in both RMD and placebo groups (p < 0.01 each).Table 3Change in stool volume and stool consistency for each group during 3-week intervention  Interestingly, analysis of the individual Rome III criteria showed that only after intervention with RMD a significant lower number of subjects (compared to baseline) answered positively to 3 out of 6 criteria: \"straining\" (from 63.6 to 33.3 %; p < 0.025), \"sensation of incomplete evacuation\" (from 51.5 to 27.3 %; p < 0.003) in at least 25 % of defecations, as well as \"fewer than three defecations per week\" (from 24.2 to 0.0 %; p < 0.013).", "icos": [["0.9942648", "placebo", "Dietary supplementation of RMD", "\" sensation of incomplete evacuation \""], ["0.99011", "placebo", "RMD supplementation", "\" sensation of incomplete evacuation \""], ["0.9895732", "placebo", "radiopaque markers", "\" sensation of incomplete evacuation \""], ["0.98918694", "placebo", "DF intake", "\" sensation of incomplete evacuation \""], ["0.9886531", "placebo", "RMD", "\" sensation of incomplete evacuation \""]], "sample": "c"}
